Puma Biotechnology (NASDAQ: PBYI) insider transactions
In the twelve months to 10 November 2026, executives and directors of Puma Biotechnology reported 17 open-market sales of 283,446 shares ($2.1m) and 0 open-market purchases, by 10 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 14 September 2026 | Cesano Alessandra | Director | Option exercise, 10b5-1 plan | +50,000 | $2.93 | 118,850 | Form 4 |
| 14 September 2026 | Cesano Alessandra | Director | Open-market sale, 10b5-1 plan | −62,150 | $9.12 | 56,700 | Form 4 |
| 14 September 2026 | Wilson Troy Edward | Director | Open-market sale, 10b5-1 plan | −5,000 | $9.10 | 54,750 | Form 4 |
| 6 July 2026 | Nougues Maximo F | Chief Financial Officer | Open-market sale, 10b5-1 plan | −9,386 | $8.26 | 230,637 | Form 4 |
| 6 July 2026 | Hunt Douglas M | See Remarks | Open-market sale, 10b5-1 plan | −8,460 | $8.26 | 196,841 | Form 4 |
| 6 July 2026 | Auerbach Alan H | President and CEO | Open-market sale, 10b5-1 plan | −44,058 | $8.26 | 7,261,671 | Form 4 |
| 12 June 2026 | Dorval Allison | Director | Open-market sale, 10b5-1 plan | −11,610 | $7.20 | 90,780 | Form 4 |
| 12 June 2026 | Moyes Jay M | Director | Open-market sale, 10b5-1 plan | −22,000 | $7.22 | 58,322 | Form 4 |
| 12 June 2026 | Senderowicz Adrian | Director | Open-market sale, 10b5-1 plan | −27,000 | $7.20 | 27,000 | Form 4 |
| 12 June 2026 | Stuglik Brian M | Director | Open-market sale, 10b5-1 plan | −8,100 | $7.20 | 113,858 | Form 4 |
| 12 June 2026 | Wilson Troy Edward | Director | Open-market sale, 10b5-1 plan | −10,800 | $7.20 | 59,750 | Form 4 |
| 11 June 2026 | Cesano Alessandra | Director | Grant or award | +27,000 | — | 68,850 | Form 4 |
| 11 June 2026 | Dorval Allison | Director | Grant or award, 10b5-1 plan | +27,000 | — | 102,390 | Form 4 |
| 11 June 2026 | Moyes Jay M | Director | Grant or award, 10b5-1 plan | +27,000 | — | 80,322 | Form 4 |
| 11 June 2026 | Miller Michael Patrick | Director | Grant or award | +27,000 | — | 81,000 | Form 4 |
| 11 June 2026 | Senderowicz Adrian | Director | Grant or award, 10b5-1 plan | +27,000 | — | 54,000 | Form 4 |
| 11 June 2026 | Stuglik Brian M | Director | Grant or award, 10b5-1 plan | +27,000 | — | 121,958 | Form 4 |
| 11 June 2026 | Wilson Troy Edward | Director | Grant or award, 10b5-1 plan | +27,000 | — | 70,550 | Form 4 |
| 18 February 2026 | Nougues Maximo F | Chief Financial Officer | Grant or award | +46,739 | — | 240,023 | Form 4 |
| 18 February 2026 | Hunt Douglas M | See Remarks | Grant or award | +49,394 | — | 205,301 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Puma Biotechnology page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.